Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...

Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...

Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company's new schizophrenia ...

Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.

Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...

The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...

The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...

At 8:45 a.m. ET, Dow E-minis were up 90 points, or 0.21%, S&P 500 E-minis were up 10.5 points, or 0.18% and Nasdaq 100 ...

US stock futures were broadly muted on Friday as investors awaited the release of a raft of economic data, including new consumer spending figures and the Federal Reserve's preferred gauge of ...

Data through the week points to a still-resilient economy overall, leaving traders uncertain about the Fed’s next move.

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

A Commerce Department report, due at 8:30 a.m. ET, is expected to show the Personal Consumption Expenditure Index - the Fed's ...